Is Vertex Pharmaceuticals Stock Too Expensive With a Price-to-Sales Ratio of 11x?

I've been a big fan of Vertex Pharmaceuticals (VRTX 0.44%), and the biotech stock has made me a lot of money throughout the years. Vertex continues to enjoy a virtual monopoly in treating cystic fibrosis (CF) but it's advancing multiple promising programs in its pipeline.However, investors who watch valuation metrics closely might have noticed something concerning about Vertex: Its shares trade at a price-to-sales (P/S) ratio of over 11x. Is Vertex stock too expensive right now?Relatively speakingLet's ackn ...